Q2 2019 EPS Estimates for Endo International PLC Reduced by Svb Leerink (ENDP)

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Stock analysts at Svb Leerink cut their Q2 2019 earnings estimates for shares of Endo International in a research note issued to investors on Thursday, April 18th, according to Zacks Investment Research. Svb Leerink analyst A. Fadia now expects that the company will post earnings per share of $0.52 for the quarter, down from their prior estimate of $0.53. Svb Leerink has a “Market Perform” rating on the stock. Svb Leerink also issued estimates for Endo International’s Q3 2019 earnings at $0.59 EPS, Q4 2019 earnings at $0.67 EPS, FY2022 earnings at $1.10 EPS and FY2023 earnings at $1.12 EPS.

Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings results on Thursday, May 9th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.42 by $0.11. The company had revenue of $720.00 million during the quarter, compared to analysts’ expectations of $692.31 million. Endo International had a negative return on equity of 199.18% and a negative net margin of 18.35%. The firm’s revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.67 EPS.

Other equities analysts have also issued reports about the company. Zacks Investment Research raised Endo International from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research note on Thursday, January 17th. Canaccord Genuity set a $17.00 price objective on Endo International and gave the company a “buy” rating in a research note on Friday, March 8th. SunTrust Banks initiated coverage on Endo International in a research note on Tuesday, March 19th. They issued a “buy” rating and a $13.00 price objective on the stock. BidaskClub raised Endo International from a “hold” rating to a “buy” rating in a research note on Thursday, March 21st. Finally, ValuEngine raised Endo International from a “sell” rating to a “hold” rating in a research note on Tuesday, March 12th. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $15.44.

Shares of NASDAQ ENDP traded up $0.05 during midday trading on Friday, hitting $8.06. The stock had a trading volume of 4,070,899 shares, compared to its average volume of 2,701,650. The firm has a market capitalization of $1.81 billion, a P/E ratio of 2.79 and a beta of 1.12. Endo International has a 1-year low of $5.92 and a 1-year high of $18.50.

A number of institutional investors have recently added to or reduced their stakes in ENDP. Norges Bank acquired a new position in Endo International during the 4th quarter worth approximately $21,218,000. Teachers Advisors LLC raised its position in shares of Endo International by 230.1% in the 3rd quarter. Teachers Advisors LLC now owns 1,468,025 shares of the company’s stock valued at $24,707,000 after purchasing an additional 1,023,350 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Endo International by 83,573.5% in the 1st quarter. Acadian Asset Management LLC now owns 771,470 shares of the company’s stock valued at $6,194,000 after purchasing an additional 770,548 shares in the last quarter. Canada Pension Plan Investment Board raised its position in shares of Endo International by 143,723.6% in the 4th quarter. Canada Pension Plan Investment Board now owns 730,624 shares of the company’s stock valued at $5,333,000 after purchasing an additional 730,116 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund acquired a new position in shares of Endo International in the 4th quarter valued at approximately $76,000. 95.03% of the stock is currently owned by hedge funds and other institutional investors.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Further Reading: P/E Growth (PEG)

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.